1. A Comparative Review of Waivers Granted in Pediatric Drug Development by FDA and EMA From 2007-2013. (September 2016) Authors: Egger, Gunter F.; Wharton, Gerold T.; Malli, Suzanne; Temeck, Jean; Murphy, M. Dianne; Tomasi, Paolo Journal: Therapeutic innovation & regulatory science Issue: Volume 50:Number 5(2016:Sep.) Page Start: 639 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Inclusion of Infants and Neonates in Pediatric Orphan Product Approvals. Issue 4 (14th June 2021) Authors: Park, Kyunghun; Virparia, Riddhi; Green, Dionna J.; Epps, Carla; Wharton, Gerold T.; McCune, Susan K.; Burckart, Gilbert J. Journal: Clinical pharmacology & therapeutics Issue: Volume 110:Issue 4(2021) Page Start: 997 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Octreotide use and safety in infants with hyperinsulinism. Issue 1 (2nd December 2016) Authors: McMahon, Ann W.; Wharton, Gerold T.; Thornton, Paul; De Leon, Diva D. Journal: Pharmacoepidemiology and drug safety Issue: Volume 26:Issue 1(2017) Page Start: 26 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Pediatric post‐marketing safety systems in North America: assessment of the current status†. (22nd June 2015) Authors: McMahon, Ann W.; Wharton, Gerold T.; Bonnel, Renan; DeCelle, Mary; Swank, Kimberley; Testoni, Daniela; Cope, Judith U.; Smith, Phillip Brian; Wu, Eileen; Murphy, Mary Dianne Journal: Pharmacoepidemiology and drug safety Issue: Volume 24:Number 8(2015:Aug.) Page Start: 785 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗